Compare ALUR & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | LEXX |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | ALUR | LEXX |
|---|---|---|
| Price | $1.48 | $0.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.25 | $1.50 |
| AVG Volume (30 Days) | 109.6K | ★ 307.9K |
| Earning Date | 11-12-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | $522,000.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | $15.47 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.05 |
| 52 Week Low | $1.02 | $0.46 |
| 52 Week High | $7.40 | $1.91 |
| Indicator | ALUR | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 46.05 |
| Support Level | $1.28 | $0.71 |
| Resistance Level | $1.57 | $0.86 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 32.31 | 43.00 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.